22 results about "Cervical cancer" patented technology

The present application relates to a kind of five-ring thiazole indole ketone piperazine amide derivatives and purposes thereof.The derivatives take ethyl cyanoacetate as starting material, generate hydroxylamine compound (A) under the action of sodium nitrite and phosphoric acid;Obtain 2-amino ethyl cyanoacetate (B) by reduction, in turn with acetic anhydride, lawson reagent is reacted, and 5-amino-4-carboxylate thiazole compound (D) is obtained;After bromination by NBS, under the catalysis of phosphorus oxychloride, react with tetrahydropyridine indole ketone, generate 2-bromo-6,7-dihydrothiazolo [5'',4'':4',5'] pyrimido [1',2':1,2] pyrindo [3,4-b] indole-4 (12H) -ketone (F), again under alkaline condition, first with Boc piperazine, then by Boc treatment and obtain compound (H);Finally, react with acyl chloride, and 28 different substitution structures of five-ring thiazole indole ketone piperazine amide compound (I1-I28) are synthesized.The 28 compounds are tested on three kinds of cancer cells, and the results show that: 28 compounds have significant inhibitory activity on Hela cervical cancer cells, HT-29 human colon cancer cells and HGC-27 human gastric cancer cells.

This invention discloses a lipid nanoparticle co-delivery system based on phenolic hydroxyl lipids and a manganese adjuvant. Addressing the shortcomings of traditional HPV therapeutic peptide vaccines—weak immunogenicity, easy degradation and inactivation in vivo, low bioavailability of manganese ion adjuvants making spatiotemporal co-delivery with antigens, and poor encapsulation efficiency and insufficient biosafety of conventional lipid nanocarriers—this invention constructs an integrated nanovaccine delivery system by embedding phenolic hydroxyl functional lipids into a nanocarrier framework, synergistically loading HPV E6 / E7 specific antigen peptides and manganese ion immune adjuvants. This system achieves efficient delivery, immune activation, and anti-tumor efficacy, integrating the functions of efficient antigen delivery, potent immune activation, and precise anti-tumor action. The preparation process is simple and exhibits excellent stability, overcoming the limitations of traditional HPV peptide vaccines with poor efficacy when used alone. It has broad research value and clinical translation prospects in the field of precision immunotherapy for HPV-related cervical cancer, head and neck squamous cell carcinoma, and other malignant tumors.

This disclosure particularly relates to combination therapy of oncolytic adenoviruses with topoisomerase I inhibitors or their prodrugs (such as topotecan or SN-38) or prodrugs of topoisomerase inhibitors (such as irinotecan) for the treatment or prevention of ovarian cancer, cervical cancer, lung cancer, colon or colorectal cancer and / or pancreatic cancer.

The application provides a primer probe combination for detecting HPV16 and HPV18 by using microdroplet digital PCR and application thereof, and belongs to the technical field of human papilloma virus detection products. The primer probe combination for detecting HPV16 and HPV18 by using microdroplet digital PCR comprises a multi-target primer probe combination for detecting HPV16, and a multi-target primer probe combination for detecting HPV18, wherein the nucleotide sequence of the primer probe combination for detecting HPV16 is shown in SEQ ID NO. 1-27, and the nucleotide sequence of the primer probe combination for detecting HPV18 is shown in SEQ ID NO. 28-54. The primer probe combination has high sensitivity and low detection limit, can accurately detect HPV16 and HPV18 with high specificity and low cost, accurately capture trace ctDNA in early cervical cancer patient samples, significantly improve the early diagnosis rate, and effectively avoid the missed detection risk of single detection.

The present application relates to a kind of preparation method and application of HPV recombinant protein therapeutic vaccine, belong to biological medicine technical field, the preparation method of the HPV recombinant protein therapeutic vaccine described includes: a plurality of complex lipid nanoparticles prepared by lipid are simultaneously wrapped and delivered HPV16HPV E6E7 recombinant protein antigen and nucleic acid TLR agonist adjuvant molecule.This application is beneficial to the recombinant protein therapeutic vaccine prepared to induce strong T cell immune response to HPV16E6E7 antigen, kill the cervical cancer cell infected by HPV.In addition, unlike the lipid nanoparticle (LNP) of mRNA vaccine delivery, there is no cation or ionizable lipid in the formula, significantly higher than mRNA vaccine in safety, with greater advantage than mRNA therapeutic vaccine, and low toxicity and side effects, vaccine effect is stable.

This invention belongs to the fields of medicinal chemistry and pharmaceutical technology, and relates to 1,4-benzodiazepines and their use in the preparation of antitumor drugs, specifically the use of 1,4-benzodiazepines in the preparation of annexin A3 (ANXA3) degrading agents and in the preparation of drugs for treating cancer. In particular, it discloses the use of 1,4-benzodiazepines, or pharmaceutically acceptable salts thereof, or stereoisomers thereof, or compositions of drugs with these as active ingredients, in the preparation of drugs for the prevention and treatment of tumors. These compounds can bind to the ANXA3 protein, induce ANXA3 protein degradation, inhibit the proliferation, cloning, migration, and invasion of tumor cells, and exert antitumor therapeutic effects in vivo. They can be used to treat solid tumors and hematological malignancies, including breast cancer, cervical cancer, ovarian cancer, colorectal cancer, gastric cancer, pancreatic cancer, lung cancer, esophageal cancer, liver cancer, leukemia, and melanoma.

The application relates to the technical field of pharmaceutical chemistry, and discloses a sulfuryl hydrazone compound, a preparation method thereof and anti-tumor application. The compound is synthesized from isatin derivatives and sulfuryl hydrazine through two-step nucleophilic substitution-elimination reaction, has a chemical structure as shown in formula (I), and is characterized by 1H NMR, 13C NMR and HRMS. The sulfuryl hydrazone compound has significant inhibitory activity on A549 (lung cancer), HepG2 (liver cancer) and Hela (cervical cancer) three human cancer cell strains, the value of some compounds is as low as 0.03 micromole / L, the compound can induce cell apoptosis by mediating ROS generation in tumor cells, inhibiting the NF-kappa B signal pathway and activating Caspase-3 activity, and can effectively inhibit cancer cell migration and colony formation. The compound has a mild synthesis process, simple operation and wide substrate applicability, can be used as a potential anti-tumor active ingredient, can be used for preparing drugs for resisting lung cancer, liver cancer, cervical cancer and other tumors, and can provide new candidate compounds and technical support for cancer treatment.

The application discloses application of coccinellin in antitumor drugs and the drugs, wherein the coccinellin has a molecular formula of C 14 H 10 N2O5, and the tumor includes at least one of colorectal cancer, pancreatic cancer, lung cancer, liver cancer, gastric cancer, thyroid cancer, kidney cancer, bladder cancer, ovarian cancer, cervical cancer, breast cancer, myeloma, hemangioma and central nervous system tumor. The antitumor mechanism of the coccinellin is to inhibit KRAS G12D mutant subtype. The coccinellin can effectively inhibit proliferation of various tumor cells, and is expected to be applied to tumor treatment as an antitumor small molecule targeted drug.

The application discloses an anti-tumor N-acetyl-D-glucosamine compound wine and a preparation method thereof, and belongs to the technical field of medicines. The anti-tumor N-acetyl-D-glucosamine compound wine provided by the application is characterized by comprising active ingredients and base wine; the active ingredients comprise N-acetyl-D-glucosamine, smilax riparian root, agrimony, oldenlandia, medlar and licorice. In the preparation, the traditional Chinese medicine components are first soaked and extracted by the base wine, then N-acetyl-D-glucosamine is added for dissolution, and the anti-tumor N-acetyl-D-glucosamine compound wine is obtained through aging and filling. The N-acetyl-D-glucosamine is compounded with traditional Chinese medicine such as smilax riparian root and agrimony for the first time, and the synergistic effect is exerted through the wine form. The in-vitro cell experiment and in-vivo animal experiment prove that the compound wine has a significant inhibitory effect on various tumor cells such as liver cancer, lung cancer and cervical cancer, and the effect is obviously better than that of the comparative examples; and the preparation process is simple and suitable for industrial production.

The present invention relates to a FLT3L–flagellin hybrid adjuvant with enhanced antigen cross-presentation efficacy and a vaccine composition comprising same. The hybrid adjuvant of the present invention demonstrated significant therapeutic efficacy as an adjuvant for a therapeutic cancer vaccine in a preclinical mouse model of cervical cancer, resulting in complete tumor regression and sustained protection. In addition, the hybrid adjuvant of the present invention induced tumor-specific antigen CD8+ T cell responses and progenitor-exhausted CD8+ T cells (Tpex) due to an increase in cross-presentation by conventional type 1 dendritic cells (cDC1) in tumor-draining lymph nodes and the tumor microenvironment, and the combination of TCV having the hybrid adjuvant applied thereto and anti-PD-1 therapy significantly improves survival outcomes in anti-PD-1–resistant tumors, and thus can be advantageously applied in anticancer immunotherapy using therapeutic cancer vaccines.

The application discloses matrine 14-position spiro derivative and a preparation method and application thereof, and belongs to the technical field of pharmacy. The application takes matrine as raw material, synthesizes matrine diazonium at the 14-position as a reaction intermediate, and synthesizes 26 matrine 14-position spiro derivatives through [3+2] cycloaddition reaction with acrylic ester compounds at normal temperature without a catalyst. The synthesized compounds are subjected to preliminary screening of in-vitro anti-tumor activity by selecting human liver cancer cells HepG2, human cervical cancer cells Hela and rat neuroglioma cells C6. The target compounds all show good anti-tumor activity, indicating that the compounds are anti-tumor drugs with development prospects, and can provide a reference for further development of matrine as an anti-tumor drug.

The present disclosure provides methods of treatment comprising anti-EDB antibodies and antibody-drug conjugates. The present disclosure further provides methods of treating EDB+ FN-expressing disorders, such as cancer. In some aspects, the method comprises administration of an anti-EDB+FN ADC to a patient having cancer, such as, for example, non-small cell lung cancer (NSCLC), breast cancer, head and neck cancer, ovarian cancer, thyroid cancer, pancreatic cancer, soft tissue sarcoma, chordoma, hepatocellular carcinoma, kidney cancer, cervical cancer, and endometrial cancer.

The application discloses a HeLa cell three-dimensional culture model, a preparation method and application. HeLa cells are mixed with a collagen-sodium alginate composite hydrogel precursor solution to obtain a cell-precursor mixture, the cell-precursor mixture is mixed with a CaCl2 solution to obtain a mixed solution, and the mixed solution is placed in an incubator for standing culture for 10-60 min, so that the hydrogel is cross-linked and solidified to form a three-dimensional culture system; complete culture medium is further added for continuous culture, and a HeLa cell three-dimensional culture model is constructed. The HeLa cell three-dimensional culture model is constructed by using the hydrogel, defects existing in simulation of a tumor microenvironment by two-dimensional culture and an animal model are effectively solved, the body microenvironment can be better simulated, cells form regular three-dimensional cell spheroids, a malignant phenotype is maintained, the accuracy and repeatability of drug screening are improved, and a reliable technical platform is provided for cervical cancer mechanism research and anti-tumor drug screening.

This invention relates to the field of Lithospermum erythrorhizon isolation and purification technology, specifically a method for extracting and separating benzoquinone components from Lithospermum erythrorhizon in Xinjiang, and its application in antitumor drugs. The method involves extracting and concentrating the dried roots of Lithospermum erythrorhizon by ethanol reflux. The concentrated extract is then further extracted and concentrated. The resulting petroleum ether fraction is subjected to chromatographic separation and gradient elution, followed by colorimetric analysis. Ten similar components are combined. The first concentrate is then separated, subjected to gradient elution, and subjected to colorimetric analysis, resulting in the combination of seven similar components. The second concentrate is then separated, subjected to gradient elution, and subjected to colorimetric analysis, resulting in the combination of nine similar components. The third concentrate is then separated and purified to obtain the final product. This invention features a simple process, environmental friendliness, and high product purity. It is the first time that benzoquinone components from Lithospermum erythrorhizon in Xinjiang have been obtained. In vitro activity verification has shown that these components exhibit inhibitory activity against HeLa tumor cells, and they can be applied to the extraction and separation of drugs for the prevention and / or anti-cervical cancer.

The present disclosure is concerned with compounds that restore p53 activity and methods of using the compounds in the treatment of various disorders related to loss of p53 activity such as, for example, cancer (e.g., a sarcoma, a carcinoma, a head-and-neck cancer, hematological cancer, a solid tumor, breast cancer, cervical cancer, gastrointestinal cancer, colorectal cancer, brain cancer, skin cancer, prostate cancer, ovarian cancer, thyroid cancer, testicular cancer, pancreatic cancer, liver cancer, endometrial cancer, melanoma, a glioma, leukemia, lymphoma, chronic myeloproliferative disorder, myelodysplastic syndrome, myeloproliferative neoplasm, non-small cell lung carcinoma, small cell lung carcinoma, renal cancer, lung cancer, colon cancer, cervical cancer, and plasma cell neoplasm (myeloma)). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

The objective is to provide a composition that can suppress diseases other than oral diseases. [Solution] The present invention is a growth inhibitor for Fusobacterium bacteria containing cyclodextran and / or its derivatives. Due to its inhibitory effect on Fusobacterium bacteria, it contributes to the treatment and prevention of ulcerative colitis, liver cirrhosis, obesity, colorectal cancer, esophageal cancer, oral cancer, breast cancer, ovarian cancer, cervical cancer, oral squamous cell carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, premature birth, and endometriosis ulcers.

This invention discloses a BCG biomimetic vesicle and its application in the preparation of tumor nanovaccines, belonging to the field of tumor vaccines. The invention uses BCG strains or recombinant BCG strains as raw materials, and through a reduction-chelation-enzymatic hydrolysis synergistic cell disruption and high-pressure homogenization recombination process, produces BCG biomimetic vesicles and membrane-anchored tumor antigen genes. The BCG biomimetic vesicles prepared with BCG strains can efficiently induce BMDCs to establish training immune memory, while simultaneously promoting the differentiation of memory T cells and NK cell activation in lymph nodes, indirectly stimulating acquired immune responses, thereby inhibiting cervical cancer tumor growth. The BCG biomimetic vesicles prepared with recombinant BCG strains can synergistically activate lymph node acquired immunity and training immunity-mediated innate immunity, inhibiting the growth of HPV-related subcutaneous xenografts. This invention provides a candidate strategy for the immunotherapy of HPV-related tumors, with clear clinical application prospects and industrial value.

This invention discloses terpenoid compounds with anticancer activity and their preparation methods, belonging to the field of biotechnology. The invention employs a chemical-enzymatic method, first chemically synthesizing the natural substrate analog 7-O-FPP, and then using the sesquiterpene synthase TmS for in vitro catalysis to obtain three oxygen-containing sesquiterpene products. MTT activity assays showed that the three compounds exhibited significant anticancer activity against gastric cancer SGC7901, lung cancer NCI-H1975, cervical cancer HeLa, and esophageal squamous cell carcinoma KYSE-150 cells. Compounds 1 and 3 showed anticancer activity against various cancer cell lines. 50 The concentration of compounds below 1 μg / mL showed significantly superior activity compared to the clinical drug β-elemene; compound 2 exhibited higher activity against lung cancer cells and low toxicity to normal MRC-5 cells. This invention provides an efficient method for preparing novel terpenoid compounds, and the resulting compounds offer high-quality lead molecules for the development of new anticancer drugs, demonstrating promising application prospects.

This invention discloses a vaginal inflatable anti-adhesion dilator, dilation method, and control method, relating to the field of medical device technology. It includes a main inflatable balloon unit that can be inserted into the vagina, a manual inflation control unit, and a safety monitoring unit. The main inflatable balloon unit has an elastic diaphragm that divides it into a proximal balloon corresponding to the cervix and a distal balloon corresponding to the vaginal opening. The main inflatable balloon unit is equipped with an independent control valve for switching inflation channels, and its outer surface has micro-protrusions. This invention, through segmented balloons adapted to the pathological differences in different vaginal segments, combined with an independent valve and safety monitoring unit, improves safety and comfort, is suitable for home-based self-rehabilitation scenarios, and provides a convenient and effective dilation solution for patients with vaginal stenosis after cervical cancer radiotherapy.

This invention relates to a pentacyclic thiazole indole sulfonyl piperazine derivative and its uses. The synthesis of this derivative begins with ethyl cyanoacetate as the starting material, which, under the synergistic effect of sodium nitrite and phosphoric acid, generates a hydroxylamine compound (1); after reduction, ethyl 2-aminocyanoacetate (2) is obtained, which is then reacted sequentially with acetic anhydride and Lawson's reagent to obtain a 5-amino-4-carboxylate thiazole compound (4); after NBS bromination, it reacts with tetrahydropyridine indole ketone under the catalysis of phosphorus oxychloride to generate 2-bromo-6,7-dihydrothiazo[5'',4'':4',5']pyrimidin[ [1',2':1,2]pyrido[3,4-b]indole-4(12H)-one (6) was first reacted with Boc piperazine under alkaline conditions, and then deprotected by Boc to obtain compound (8); finally, it was reacted with sulfonyl chloride to synthesize 28 pentacyclic thiazole indole one sulfonyl piperazine compounds 9a-9ab. The inhibitory activity of these 28 compounds against HeLa cervical cancer cells, HT-29 human colon cancer cells and HGC-27 human gastric cancer cells was investigated.

A system and methods for treating gastrointestinal, lung, breast, stomach, liver, pancreas, ovary, prostate, small bowel, bladder, kidney, uterine cervix, thyroid and bone marrow cancers are performed where the nerve is selected from the vagus nerve and its individual branches and / or splanchnic nerve, and / or celiac complex. In embodiments, at least one electrode is placed on or near the vagus nerve. In each of the aforementioned embodiments, the electrical signal therapy can be combined with administration of therapeutic agents that affects the growth or proliferation cancerous cells.